TB-500 vs GHK-Cu
Both compounds appear in the regeneration-research literature, but they operate through different mechanisms and in different primary model systems. TB-500 (the active fragment of thymosin β4) modulates actin-cytoskeleton dynamics and cell migration. GHK-Cu engages copper-mediated antioxidant and matrix-remodeling chemistry. This page summarises how the published research separates them.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Structural class | 17-residue synthetic fragment of thymosin β4 | Tripeptide-copper(II) complex (Gly-His-Lys with bound Cu²⁺) |
| Approximate molecular weight | 1888.2 g/mol | 402.91 g/mol (Cu-bound form) |
| Best-studied mechanism | G-actin sequestration, F-actin equilibrium modulation, cell-migration kinetics | Copper-mediated antioxidant chemistry, integrin/p63 expression, MMP/collagen expression |
| Primary tissues in literature | Cardiac tissue, corneal epithelium, vascular endothelium, dermal wound bed | Dermal fibroblast, keratinocyte, hair follicle, wound bed extracellular matrix |
| Common research routes | IM and SC in rodent studies; topical in ocular and dermal work | Topical in dermatology; SC in some in-vivo studies |
| Distinctive feature | Conserved Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln actin-binding motif | Bound copper ion integral to the active species |
| Reconstitution | Bacteriostatic water; lyophilised vial format | Bacteriostatic water; lyophilised vial format; protect from oxidising conditions |
| Ronin catalog vial size | 10 mg lyophilised | 50 mg lyophilised |
How they differ in mechanism
TB-500 operates through actin-cytoskeleton modulation. The conserved actin-binding motif binds monomeric G-actin in 1:1 stoichiometry, modulating the equilibrium between G-actin and F-actin filaments. Downstream of that biochemistry, the published literature reports altered cell-migration kinetics across endothelial, epithelial, and cardiac cell types and changes in markers associated with cell-cycle re-entry in normally post-mitotic tissue.
GHK-Cu operates through copper-bound tripeptide chemistry. The published mechanistic literature reports quenching of reactive carbonyl species, modulation of integrin and p63 expression in keratinocytes, and altered matrix metalloproteinase and collagen expression in dermal fibroblasts. The copper ion is integral to the active species; uncomplexed GHK does not reproduce the same chemistry profile.
The two mechanisms are non-overlapping. TB-500 modulates cytoskeletal dynamics and cell-migration biology. GHK-Cu modulates extracellular-matrix remodeling and copper-dependent antioxidant chemistry. The shared territory is the regeneration framing, but the mechanistic targets and primary model systems differ.
How research has examined each
The TB-500 / thymosin β4 literature is concentrated in cardiac repair, corneal wound healing, and dermal regeneration. The cardiac-repair line traces to Bock-Marquette and colleagues (Nature, 2004) characterising epicardial-cell migration and cardiac-cell survival. The corneal literature describes re-epithelialisation acceleration in chemical and mechanical injury models.
The GHK-Cu literature is concentrated in dermal regeneration, hair-follicle research, and oxidative-stress chemistry. Pickart and colleagues have published extensively since the 1980s on the tripeptide’s biology, including integrin and p63 expression effects in keratinocytes and matrix-remodeling effects in dermal fibroblasts. The gene-expression literature extends to neural-pathway gene expression.
The two literatures rarely cite one another directly. Both appear in survey reviews of peptide-based regeneration research positioned alongside BPC-157, KPV, and MOTS-c as a class. The primary mechanistic and model-system citations remain non-overlapping.
Stacking considerations in research contexts
The two compounds appear together in some multi-component research formulations (Glow Blend, KLOW Blend) that combine TB-500 with GHK-Cu and BPC-157 for broad-spectrum tissue-remodeling research applications. However, combined-administration pharmacology studies of this specific pair in the indexed published literature are absent. Both are available as separate single-compound vials in the Ronin catalog for investigators sourcing per-compound vials.
Sourcing both at Ronin
Both compounds ship as lyophilised peptide in glass vials with certificate-of-analysis documentation. The TB-500 vial page (10 mg) and the GHK-Cu vial page (50 mg) carry per-compound spec sheets. Both are sold strictly as research-grade reagents for laboratory and bench-research applications.
Frequently asked research questions
Are they chemically related?
No. TB-500 is a 17-residue thymosin β4 fragment. GHK-Cu is a 3-residue tripeptide-copper complex. They share neither sequence homology nor common precursor.
Why are the vial sizes different?
GHK-Cu has a much lower molecular weight (~403 g/mol vs ~1888 g/mol) and published research uses larger absolute mass amounts per dose. The 50 mg vial size is the standard vendor convention for GHK-Cu.
Do they work through the same mechanism?
No. TB-500 modulates actin-cytoskeleton dynamics. GHK-Cu modulates copper-dependent extracellular-matrix remodeling and antioxidant chemistry. The mechanisms are non-overlapping.
Are they co-administered in research protocols?
They appear together in some multi-component research formulations (Glow Blend, KLOW Blend), but combined-administration pharmacology studies of this specific pair are absent from the indexed published literature.
Are either approved for human therapeutic use?
Neither compound is approved by the FDA or Health Canada as a human therapeutic. Both are sold strictly as research-grade reagents.
References
- Malinda KM et al. Thymosin β4 stimulates directional migration of human umbilical vein endothelial cells. FASEB Journal, 1997. [PMID 9194528]
- Bock-Marquette I et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration. Nature, 2004. [PMID 15565145]
- Sosne G et al. Thymosin β4 promotes corneal wound healing. Experimental Eye Research, 2002. [PMID 11950239]
- Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science Polymer Edition, 2008. [PMID 18644225]
- Kang YA et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Archives of Dermatological Research, 2009. [PMID 19319546]
- Pickart L et al. The human tripeptide GHK-Cu in prevention of oxidative stress. Oxidative Medicine and Cellular Longevity, 2012. [PMID 22666519]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.